Skip header and navigation

Refine By

18 records – page 1 of 2.

Anti-Müllerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study.

https://arctichealth.org/en/permalink/ahliterature263591
Source
Hum Reprod. 2014 Oct 10;29(10):2317-25
Publication Type
Article
Date
Oct-10-2014
Author
P. Pinola
L C Morin-Papunen
A. Bloigu
K. Puukka
A. Ruokonen
M-R Järvelin
S. Franks
J S Tapanainen
H. Lashen
Source
Hum Reprod. 2014 Oct 10;29(10):2317-25
Date
Oct-10-2014
Language
English
Publication Type
Article
Keywords
Adolescent
Adolescent Development
Adult
Amenorrhea - blood
Anti-Mullerian Hormone - blood
Biological Markers - blood - metabolism
Cohort Studies
Female
Finland
Humans
Polycystic Ovary Syndrome - diagnosis - metabolism
Prospective Studies
Testosterone - blood
Abstract
Can serum anti-M?llerian hormone (AMH) levels measured in female adolescents predict polycystic ovary syndrome (PCOS)-associated features in adolescence and early adulthood?
AMH levels associated well with PCOS-associated features (such as testosterone levels and oligoamenorrhoea) in adolescence, but was not an ideal marker to predict PCOS-associated features in early adulthood.
Several studies have reported that there is a strong correlation between antral follicle count and serum AMH levels and that women with PCOS/PCO have significantly higher serum AMH levels than women with normal ovaries. Other studies have reported an association between AMH serum levels and hyperandrogenism in adolescence, but none has prospectively assessed AMH as a risk predictor for developing features of PCOS during adulthood.
A subset of 400 girls was selected from the prospective population-based Northern Finland Birth Cohort 1986 (n = 4567 at age 16 and n = 4503 at age 26). The population has been followed from 1986 to the present.
At age 16, 400 girls (100 from each testosterone quartile: 50 with oligo- or amenorrhoea and 50 with a normal menstrual cycle) were selected at random from the cohort for AMH measurement. Metabolic parameters were also assessed at age 16 in all participants. Postal questionnaires enquired about oligo- or amenorrhoea, hirsutism, contraceptive use and reproductive health at ages 16 and 26.
There was a significant correlation between AMH and testosterone at age 16 (r = 0.36, P
Notes
Cites: Ann Clin Biochem. 2011 Jul;48(Pt 4):370-321628625
Cites: Endocrine. 2009 Oct;36(2):339-4519714502
Cites: Hum Reprod. 2009 Nov;24(11):2917-2319617605
Cites: Clin Endocrinol (Oxf). 2010 Jan;72(1):26-3119438903
Cites: J Clin Endocrinol Metab. 2010 Apr;95(4):1786-9220150576
Cites: Fertil Steril. 2010 Aug;94(3):1118-2120060112
Cites: J Immunol Methods. 2010 Oct 31;362(1-2):51-920801125
Cites: Fertil Steril. 2011 Jul;96(1):230-521549367
Cites: J Clin Endocrinol Metab. 2003 Dec;88(12):5957-6214671196
Cites: Hum Reprod. 2004 Jan;19(1):41-714688154
Cites: Mol Cell Endocrinol. 2003 Dec 15;211(1-2):85-9014656480
Cites: Fertil Steril. 2011 Sep;96(3):774-921737073
Cites: Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):254-921752527
Cites: Hum Reprod. 2011 Nov;26(11):3123-921926054
Cites: J Clin Endocrinol Metab. 2011 Nov;96(11):3432-921900380
Cites: Fertil Steril. 2012 Mar;97(3):779-8522244782
Cites: Hum Reprod. 2012 Aug;27(8):2494-50222693172
Cites: Hum Reprod. 2012 Nov;27(11):3279-8622933528
Cites: Gynecol Endocrinol. 2013 Jun;29(6):545-5023506275
Cites: PLoS One. 2013;8(5):e6451023762215
Cites: J Clin Endocrinol Metab. 2004 Jan;89(1):318-2314715867
Cites: Mol Hum Reprod. 2004 Feb;10(2):77-8314742691
Cites: Hum Reprod. 2004 May;19(5):1083-815044401
Cites: Endocrinology. 1984 Apr;114(4):1315-206546716
Cites: N Engl J Med. 1995 Sep 28;333(13):853-617651477
Cites: J Clin Endocrinol Metab. 1999 Oct;84(10):3836-4410523039
Cites: N Engl J Med. 2005 Mar 24;352(12):1223-3615788499
Cites: Hum Reprod. 2005 Jul;20(7):1820-615802325
Cites: J Clin Endocrinol Metab. 2005 Oct;90(10):5536-4316030171
Cites: J Clin Endocrinol Metab. 2006 Mar;91(3):941-516368745
Cites: Obesity (Silver Spring). 2013 Aug;21(8):1526-3223818329
Cites: Endocrinology. 1999 Dec;140(12):5789-9610579345
Cites: J Clin Endocrinol Metab. 2002 May;87(5):2013-711994334
Cites: Minerva Ginecol. 2002 Apr;54(2):97-11412032449
Cites: Reproduction. 2002 Nov;124(5):601-912416998
Cites: J Clin Endocrinol Metab. 2003 Jan;88(1):141-712519843
Cites: Int J Obes Relat Metab Disord. 2003 Jun;27(6):710-512833115
Cites: Cochrane Database Syst Rev. 2011;(7):CD00750621735412
Cites: J Clin Endocrinol Metab. 2013 Aug;98(8):3332-4023775353
Cites: Curr Opin Endocrinol Diabetes Obes. 2009 Jun;16(3):224-3119390322
PubMed ID
25056088 View in PubMed
Less detail

A biochemically distinct form of cytochrome oxidase (COX) deficiency in the Saguenay-Lac-Saint-Jean region of Quebec.

https://arctichealth.org/en/permalink/ahliterature220557
Source
Am J Hum Genet. 1993 Aug;53(2):481-7
Publication Type
Article
Date
Aug-1993
Author
F. Merante
R. Petrova-Benedict
N. MacKay
G. Mitchell
M. Lambert
C. Morin
M. De Braekeleer
R. Laframboise
R. Gagné
B H Robinson
Author Affiliation
Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
Source
Am J Hum Genet. 1993 Aug;53(2):481-7
Date
Aug-1993
Language
English
Publication Type
Article
Keywords
Acidosis, Lactic - enzymology
Amniocentesis
Brain Chemistry
Child, Preschool
Cytochrome-c Oxidase Deficiency
DNA - analysis
DNA, Mitochondrial - analysis
Electron Transport Complex IV - genetics
Fatty Liver - enzymology
Fibroblasts - enzymology
France - ethnology
Humans
Immunoblotting
Infant
Infant, Newborn
Leigh Disease - enzymology - genetics
Liver - enzymology
Organ Specificity
Quebec
RNA, Messenger - analysis
Abstract
We report the results of biochemical and molecular investigations on a group of patients from the Saguenay-Lac-Saint-Jean region of Quebec who have an unusual form of cytochrome oxidase deficiency and Leigh disease. This group can be distinguished from the classical presentation of cytochrome oxidase deficiency with Leigh disease, by the severity of the biochemical defect in different tissues. The activity in skin fibroblasts, amniocytes, and skeletal muscle of cytochrome oxidase is 50% of normal, while in kidney and heart it is close to normal values. Brain and liver, on the other hand, have very low activities. The defect in activity appears to result from a failure of assembly of the cytochrome oxidase complex in liver, but levels of mRNA for both mitochondrially encoded and nuclear-encoded subunits in liver and skin fibroblasts were found to be the same as those in controls. The cDNA sequence of the liver-specific cytochrome oxidase subunits VIa and VIIa were determined in samples from patient liver and skin fibroblasts and showed normal coding sequence.
Notes
Cites: Pediatr Res. 1977 Oct;11(10 Pt 2):1088-93904972
Cites: Am J Hum Genet. 1993 Aug;53(2):488-968392291
Cites: Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4388439
Cites: Biochemistry. 1979 Nov 27;18(24):5294-9518835
Cites: Anal Biochem. 1983 Mar;129(2):517-216303162
Cites: Ann Neurol. 1983 Aug;14(2):226-346312869
Cites: Eur J Pediatr. 1984 Jan;141(3):178-806321192
Cites: J Clin Invest. 1984 Sep;74(3):685-976432847
Cites: Biochem Soc Trans. 1985 Aug;13(4):651-32993077
Cites: J Clin Invest. 1986 May;77(5):1422-73009544
Cites: J Pediatr. 1987 Feb;110(2):216-223027293
Cites: Am J Hum Genet. 1987 Oct;41(4):584-932821802
Cites: Ann Neurol. 1987 Oct;22(4):498-5062829705
Cites: FEBS Lett. 1988 Aug 15;236(1):100-42841159
Cites: Nucleic Acids Res. 1989 Aug 11;17(15):64092549515
Cites: Nucleic Acids Res. 1989 Sep 12;17(17):71072550906
Cites: FEBS Lett. 1990 Apr 24;263(2):213-62159420
Cites: J Biol Chem. 1990 Aug 25;265(24):14220-62167310
Cites: EMBO J. 1990 Sep;9(9):2759-642167832
Cites: Pediatr Res. 1990 Nov;28(5):549-552175027
Cites: Neurology. 1991 Apr;41(4):491-81849240
Cites: Am J Hum Genet. 1992 Apr;50(4):852-81550128
Cites: Eur J Pediatr. 1992 May;151(5):347-521327797
Cites: Pediatrics. 1977 Dec;60(6):850-7202917
PubMed ID
8392290 View in PubMed
Less detail

Clinical, metabolic, and genetic aspects of cytochrome C oxidase deficiency in Saguenay-Lac-Saint-Jean.

https://arctichealth.org/en/permalink/ahliterature220556
Source
Am J Hum Genet. 1993 Aug;53(2):488-96
Publication Type
Article
Date
Aug-1993
Author
C. Morin
G. Mitchell
J. Larochelle
M. Lambert
H. Ogier
B H Robinson
M. De Braekeleer
Author Affiliation
Département de Pédiatrie, Hôpital de Chicoutimi, Québec.
Source
Am J Hum Genet. 1993 Aug;53(2):488-96
Date
Aug-1993
Language
English
Publication Type
Article
Keywords
Acidosis, Lactic - enzymology
Child
Child, Preschool
Cytochrome-c Oxidase Deficiency
Fatty Liver - enzymology
Female
France - ethnology
Gene Frequency
Genes, Recessive
Humans
Infant
Leigh Disease - enzymology - genetics - pathology
Male
Mitochondria, Liver - enzymology
Muscle Hypotonia - enzymology
Pedigree
Quebec
Abstract
Thirty-four children with lactic acidosis and Leigh encephalopathy due to cytochrome C oxidase (COX) deficiency distributed in 28 families have recently been identified in northeastern Quebec, particularly in the Saguenay-Lac-Saint-Jean (SLSJ) region. The segregation analysis was consistent with an autosomal recessive mode of inheritance. The incidence was estimated at 1/2,063 live births between 1979 and 1990, and the carrier rate was estimated at 1/23 inhabitants in SLSJ. In SLSJ, the places of origin of the COX-deficient children and their parents did not show a clustered nonuniform distribution. The genealogical reconstruction of 54 obligate carriers identified 26 ancestors common to all of them. Twenty-two were 17th-century Europeans, suggesting that the COX-deficient gene was introduced in the French-Canadian population by early settlers. These results support the hypothesis of a founder effect for COX deficiency in northeastern Quebec. Clinical findings are reported for 15 of these COX-deficient patients, age 6 mo to 11 years. Moderate developmental delay, hypotonia, ataxia, strabismus, and mild facial dysmorphism were frequent. Eleven children died in episodes of fulminant metabolic acidosis. The patients had elevated blood and cerebrospinal fluid lactate levels, decreased blood bicarbonate levels, and normal blood pH. Leigh disease and microvesicular steatosis of the liver were present in all affected patients for whom postmortem examination was performed. This biochemically uniform group of patients showed a wide range of clinical severity.
Notes
Cites: Clin Neurol Neurosurg. 1987;89(4):217-303319345
Cites: J Pediatr. 1987 Oct;111(4):525-333116190
Cites: J Pediatr. 1988 May;112(5):734-92834526
Cites: J Pediatr. 1988 Jul;113(1 Pt 1):156-93290414
Cites: J Inherit Metab Dis. 1988;11 Suppl 2:189-922846961
Cites: J Inherit Metab Dis. 1989;12(3):247-562559245
Cites: J Neurol Sci. 1990 Jan;95(1):63-762159985
Cites: Am J Hum Genet. 1990 Aug;47(2):302-72378355
Cites: Pediatr Res. 1990 Nov;28(5):536-412175026
Cites: Am J Hum Genet. 1992 Apr;50(4):852-81550128
Cites: Am J Hum Genet. 1993 Aug;53(2):481-78392290
Cites: Am J Dis Child. 1991 Jun;145(6):661-41852096
Cites: J Neurol Sci. 1991 Jul;104(1):97-1111655984
Cites: Hum Hered. 1991;41(3):168-731937490
Cites: Pediatrics. 1977 Dec;60(6):850-7202917
Cites: J Inherit Metab Dis. 1983;6(3):121-26321854
Cites: J Inherit Metab Dis. 1983;6(3):127-86422145
Cites: Brain Dev. 1984;6(4):362-726093613
Cites: Biochem Soc Trans. 1985 Aug;13(4):651-32993077
Cites: J Pediatr. 1987 Feb;110(2):216-223027293
Cites: Ann Neurol. 1987 Oct;22(4):498-5062829705
PubMed ID
8392291 View in PubMed
Less detail

Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome.

https://arctichealth.org/en/permalink/ahliterature21576
Source
J Clin Endocrinol Metab. 1998 Jul;83(7):2566-8
Publication Type
Article
Date
Jul-1998
Author
L C Morin-Papunen
R M Koivunen
C. Tomás
A. Ruokonen
H K Martikainen
Author Affiliation
Department of Obstetrics and Gynecology, University Hospital of Oulu, Finland.
Source
J Clin Endocrinol Metab. 1998 Jul;83(7):2566-8
Date
Jul-1998
Language
English
Publication Type
Article
Keywords
Adult
Analysis of Variance
Drug Administration Schedule
Female
Humans
Hypoglycemic agents - therapeutic use
Leptin
Metformin - therapeutic use
Obesity - blood - complications
Polycystic Ovary Syndrome - blood - complications - drug therapy
Proteins - metabolism
Abstract
Previous studies have suggested that metformin is clinically useful in the treatment of polycystic ovary syndrome (PCOS). The aim of this study was to evaluate whether the improvement of ovarian function achieved by metformin therapy is associated with changes in leptin concentrations. Twenty-six obese women with PCOS were treated with 500 mg metformin, x 3 daily, for 2 months; and 12 women continued the therapy for 4-6 months. A significant decrease in the serum leptin level was observed after 2 months of treatment in the whole study group (29.2 +/- 12.7 ng/mL vs. 25.7 +/- 10.9 ng/mL, P = 0.03). In the 12 women treated for 4-6 months, the mean serum leptin concentration decreased after 2 months (38.6 +/- 9.3 ng/mL vs. 30.2 +/- 8.1 ng/mL; P = 0.004) but slightly increased after 4-6 months of treatment (33.4 +/- 15.7 ng/mL; not significant). These results indicate that insulin sensitizing therapy with metformin decreases the leptin concentrations in obese PCOS women.
PubMed ID
9661644 View in PubMed
Less detail

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.

https://arctichealth.org/en/permalink/ahliterature17171
Source
Eur J Endocrinol. 2005 Feb;152(2):269-75
Publication Type
Article
Date
Feb-2005
Author
K. Rautio
J S Tapanainen
A. Ruokonen
L C Morin-Papunen
Author Affiliation
Department of Obstetrics and Gynecology, University Hospital of Oulu, PO Box 5000, FIN-90 014, Finland.
Source
Eur J Endocrinol. 2005 Feb;152(2):269-75
Date
Feb-2005
Language
English
Publication Type
Article
Keywords
Adult
Androgen Antagonists - administration & dosage
Cardiovascular Diseases - prevention & control
Cholesterol - blood
Cyproterone Acetate - administration & dosage
Ethinyl Estradiol - administration & dosage
Female
Humans
Hypoglycemic Agents - administration & dosage
Metformin - administration & dosage
Obesity - blood - complications
Polycystic Ovary Syndrome - blood - complications - drug therapy
Research Support, Non-U.S. Gov't
Treatment Outcome
Abstract
OBJECTIVE: Women with polycystic ovary syndrome (PCOS) exhibit risk factors for cardiovascular diseases such as abdominal obesity, insulin resistance and dyslipidemia. Insulin sensitizers, especially metformin, have been shown to improve these metabolic disturbances, but there are only a few studies on their effects on serum lipids in polycystic ovary syndrome. METHODS: Thirty-five women with PCOS (18 obese and 17 non-obese) were randomized to 6-month treatments with metformin or ethinyl estradiol-cyproterone acetate oral contraceptive pills. RESULTS: In the whole-study population (non-obese and obese women) serum levels of high-density lipoprotein cholesterol increased from 1.4+/-0.2 to 1.6+/-0.1 mmol/l (means +/-S.E. throughout) at 3 and 6 months (P
PubMed ID
15745936 View in PubMed
Less detail

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.

https://arctichealth.org/en/permalink/ahliterature20234
Source
J Clin Endocrinol Metab. 2000 Sep;85(9):3161-8
Publication Type
Article
Date
Sep-2000
Author
L C Morin-Papunen
I. Vauhkonen
R M Koivunen
A. Ruokonen
H K Martikainen
J S Tapanainen
Author Affiliation
Department of Obstetrics and Gynecology, University Hospital of Oulu, Finland.
Source
J Clin Endocrinol Metab. 2000 Sep;85(9):3161-8
Date
Sep-2000
Language
English
Publication Type
Article
Keywords
Adult
Androgen Antagonists - therapeutic use
Area Under Curve
Blood Glucose - metabolism
Calorimetry
Cyproterone Acetate - therapeutic use
Estradiol Congeners - therapeutic use
Ethinyl Estradiol - therapeutic use
Fats - metabolism
Female
Glucose Clamp Technique
Glucose Tolerance Test
Hormones - blood
Humans
Hypoglycemic agents - therapeutic use
Insulin - blood
Insulin Resistance - physiology
Metformin - therapeutic use
Obesity - blood - drug therapy - etiology
Polycystic Ovary Syndrome - blood - complications - drug therapy
Research Support, Non-U.S. Gov't
Abstract
Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial. Oral contraceptive pills are commonly used in the treatment of PCOS; but, like metformin, their influence on insulin sensitivity is not well known. We randomized 32 obese (body mass index > 27 kg/m2) women with PCOS, either to metformin (500 mg x 2 daily for 3 months, then 1,000 mg x 2 daily for 3 months) or to ethinyl estradiol (35 microg)-cyproterone acetate (2 mg) oral contraceptive pills (Diane Nova) for 6 months. Metformin significantly decreased the waist-to-hip ratio, serum testosterone, fasting free fatty acid, and insulin concentrations and improved oxidative glucose utilization and menstrual cyclicity, with slight (but nonsignificant) improvements in insulin hepatic extraction and insulin sensitivity. Diane Nova significantly decreased serum testosterone and increased serum sex hormone-binding globulin concentrations and glucose area under the curve during oral glucose tolerance test. It is concluded that metformin, probably by way of its effect on adipose tissue, leads to reduction of hyperinsulinemia and concomitant improvement in the menstrual pattern; and therefore, it offers a useful alternative treatment for obese, anovulatory women with PCOS. Despite slight worsening of glucose tolerance, Diane Nova is an efficient treatment for women with hyperandrogenism and hirsutism.
PubMed ID
10999803 View in PubMed
Less detail

Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.

https://arctichealth.org/en/permalink/ahliterature63102
Source
Hum Reprod. 2006 Feb 24;
Publication Type
Article
Date
Feb-24-2006
Author
K. Rautio
J S Tapanainen
A. Ruokonen
L C Morin-Papunen
Author Affiliation
Department of Obstetrics and Gynaecology, Oulu University Hospital, Oulu, Finland.
Source
Hum Reprod. 2006 Feb 24;
Date
Feb-24-2006
Language
English
Publication Type
Article
Abstract
BACKGROUND: The objective of the study was to assess the therapeutic effects of rosiglitazone in overweight women with polycystic ovary syndrome (PCOS). METHODS: A double-blind, placebo-controlled study was conducted on 30 (BMI > 25 kg/m(2), mean age 29.1 +/- 1.2 years) overweight women with PCOS treated with rosiglitazone or placebo for 4 months. Waist-to-hip ratios (WHRs), serum concentrations of sex hormones and binding proteins, blood glucose, serum insulin and serum C-peptide during a 75-g oral glucose tolerance test (OGTT), first-phase insulin secretion as determined by an intravenous glucose tolerance test (IVGTT), M values (expressing insulin sensitivity using a eug-lycaemic clamp) and calorimetric data were assessed at 0 and 4 months of treatment. RESULTS: Rosiglitazone improved menstrual cyclicity, increased serum sex hormone-binding globulin (SHBG) levels and decreased serum levels of androstenedione, 17-hydroxyprogesterone (17-OHP), dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulphate (DHEA-S). Glucose tolerance [expressed as AUCglucose during the OGTT] improved (P = 0.002) and peripheral insulin response (expressed as AUCinsulin decreased (P = 0.004) in the rosiglitazone group (ROSI group). M value improved in the ROSI group from 33.4 +/- 3.27 to 40.0 +/- 5.51 micromol/kg min (P = 0.04). CONCLUSION: Rosiglitazone, by improving menstrual cyclicity, hyperandrogenism, insulin resistance and hyperinsulinaemia, represents an alternative treatment for overweight anovulatory women with PCOS and no pregnancy desire.
PubMed ID
16501039 View in PubMed
Less detail
Source
Nouv Presse Med. 1980 Mar 12;9(17):1241-2
Publication Type
Article
Date
Mar-12-1980
Author
C. Morin
P. Dubois
M. Demas
K. Lahsinat
M. Hayet
A. Vivier
Source
Nouv Presse Med. 1980 Mar 12;9(17):1241-2
Date
Mar-12-1980
Language
French
Publication Type
Article
Keywords
Child
Female
Humans
Malaria - diagnosis
PubMed ID
7454559 View in PubMed
Less detail

Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome.

https://arctichealth.org/en/permalink/ahliterature20423
Source
Hum Reprod. 2000 Jun;15(6):1266-74
Publication Type
Article
Date
Jun-2000
Author
L C Morin-Papunen
I. Vauhkonen
R M Koivunen
A. Ruokonen
J S Tapanainen
Author Affiliation
Department of Obstetrics and Gynecology, University Hospital of Oulu, Finland.
Source
Hum Reprod. 2000 Jun;15(6):1266-74
Date
Jun-2000
Language
English
Publication Type
Article
Keywords
Adult
Body mass index
Diabetes Mellitus, Type 2 - genetics
Endocrine Glands - secretion
Fatty Acids, Nonesterified - blood
Female
Glucose - metabolism - physiology
Hormones - metabolism
Humans
Insulin - secretion
Insulin Resistance
Lipid Metabolism
Medical Records
Obesity - complications
Oxidation-Reduction
Polycystic Ovary Syndrome - complications - metabolism - physiopathology
Reference Values
Research Support, Non-U.S. Gov't
Abstract
To study the contributions of body mass, body fat distribution and family history of type 2 diabetes mellitus to hyperinsulinaemia, insulin secretion and resistance in polycystic ovarian syndrome (PCOS), 17 lean (LC) and 17 obese (OC) healthy control subjects, and 15 lean (LPCOS) and 28 obese (OPCOS) women with PCOS were investigated. Waist:hip ratio (WHR), serum concentrations of sex steroids, glucose and insulin during a 75 g oral glucose tolerance test (OGTT), and insulin and C-peptide early phase secretion, and insulin sensitivity index using a euglycaemic hyperinsulinaemic clamp were assessed. The PCOS subjects had a higher mean WHR than the controls. A trend towards hyperinsulinaemia and impairment of insulin sensitivity (including the rates of both glucose oxidation and non-oxidation) was observed in LPCOS subjects, but only in OPCOS subjects were these changes significant. Early phase insulin secretion but not the early phase C-peptide secretion was increased in PCOS subjects compared to controls, suggesting that peripheral hyperinsulinaemia in PCOS women was mainly due to the observed lowered hepatic insulin extraction and insulin resistance in skeletal muscle. Moreover, the presence of a family history of type 2 diabetes did not affect early phase insulin or C-peptide secretion in the PCOS group. These results confirm and strengthen earlier contentions, that insulin resistance is a characteristic defect in PCOS and is worsened particularly by abdominal obesity.
PubMed ID
10831553 View in PubMed
Less detail

18 records – page 1 of 2.